COMMETS- Combination MCI Metabolic Syndrome
Alzheimer Disease, Mild Cognitive Impairment, Metabolic Syndrome
About this trial
This is an interventional treatment trial for Alzheimer Disease focused on measuring Alzheimer disease, Mild Cognitive Impairment, Metabolic syndrome, Dementia, Semaglutide, Intranasal insulin
Eligibility Criteria
Inclusion Criteria: Diagnosis of MCI (based on a MOCA <27 and a clinical dementia rating scale [CDR] score of 0.5 representing questionable dementia). Diagnosis of MetS -requiring a) abdominal obesity (waist circumference >102cm for men and >88cm for women), and b) glucose intolerance (fasting glucose>110 mg/dL) and at least one of the following-c) dyslipidemia (high triglycerides [>150 mg/dL] and low HDL [<40mg/dL for men and <50 mg/dL for women]), or d) elevated blood pressure (>130/>85 mmHg). Fluent in Hebrew The study requires an active study partner Exclusion Criteria: Diabetes (of any type) Taking medications that may affect glucose metabolism (including a GLP-1RA). Diagnosis of dementia and its subtypes, conditions that may directly affect cognition, short life expectancy or a medical condition that precludes consistent participation in the study, contraindications to either insulin or Semaglutide. Medications that may affect glucose metabolism such as corticosteroids.
Sites / Locations
- Joseph Sagol Neuroscience center, Sheba Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Sham Comparator
Sham Comparator
Placebo Comparator
Group 1
Group 2
Group 3
Group 4
Will receive intranasal insulin therapy as well as Oral Semaglutide.
Will receive active intranasal insulin therapy and placebo Oral Semaglutide.
Will receive intranasal insulin placebo and active Oral Semaglutide .
Will receive intranasal insulin placebo and Oral Semaglutide placebo.